Skip to content
Evigrade
CriticalAntifungal, triazole×Third-generation dihydropyridine calcium channel blocker

Updated · Methodology

Mechanism

The enzyme CYP3A4 metabolises lercanidipine. The strong CYP3A4 inhibitor ketoconazole raised the area under the concentration curve (AUC) of the active S-enantiomer 15-fold and its peak concentration 8-fold (lercanidipine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Itraconazole also strongly inhibits CYP3A4. It has not been studied directly with lercanidipine but is likely to raise lercanidipine levels (itraconazole SmPC, AEMPS). Higher lercanidipine levels lower blood pressure further. Grapefruit juice, which inhibits lercanidipine metabolism, has the same effect (lercanidipine SmPC, AEMPS). Itraconazole also weakens heart contraction (negative inotropic effect). Calcium channel blockers can add to this effect, and together they raise the risk of congestive heart failure (itraconazole SmPC, AEMPS).

Symptoms

Excess lercanidipine dilates blood vessels too much. Blood pressure falls, with dizziness, headache, fast heart rate and palpitations. At very high doses the heart rate may instead slow down and the heart may contract more weakly (lercanidipine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The most common reactions to lercanidipine are leg swelling, flushing, headache, fast heart rate and palpitations, while fainting and angina are less common (lercanidipine SmPC, AEMPS). Congestive heart failure and oedema have been reported with itraconazole (itraconazole SmPC, AEMPS). Heart failure shows as breathlessness, leg swelling and weakness.

Management

The combination is contraindicated. The summaries of product characteristics (SmPC) of the original itraconazole product and its generics list lercanidipine among contraindicated drugs (itraconazole SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The lercanidipine SmPC contraindicates strong inhibitors of the enzyme CYP3A4 and names itraconazole under contraindicated combinations (lercanidipine SmPC, AEMPS). Do not take lercanidipine during itraconazole treatment or for two weeks after it ends (itraconazole SmPC, AEMPS). After the last dose, itraconazole levels fall to almost undetectable in 7–14 days, and even more slowly in liver cirrhosis or with other CYP3A4 inhibitors (itraconazole SmPC, AEMPS). Do not give itraconazole to people with current or past congestive heart failure, except for life-threatening or other serious infections (itraconazole SmPC, AEMPS). Tell the patient the signs of heart failure and stop itraconazole if they appear (itraconazole SmPC, AEMPS). If blood pressure falls sharply after the two drugs are taken together, give active cardiovascular support and monitor cardiovascular status for at least 24 hours, because lercanidipine acts for a long time (lercanidipine SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Itraconazole

Other interactions with Lercanidipine